^
    1d
    Optimizing Ocular Outcomes: A Dual-armed Study for Periorbital Burn Management (clinicaltrials.gov)
    P1, N=0, Withdrawn, Virginia Commonwealth University | N=10 --> 0 | Trial completion date: Jan 2027 --> Jun 2026 | Not yet recruiting --> Withdrawn | Trial primary completion date: Nov 2026 --> Jun 2026
    Enrollment change • Trial completion date • Trial withdrawal • Trial primary completion date
    |
    5-fluorouracil
    1d
    SYNCHRONOX: FOLFIRINOX Induction Chemotherapy for Synchronous Liver Metastases (clinicaltrials.gov)
    P=N/A, N=550, Recruiting, Assistance Publique - Hôpitaux de Paris | Not yet recruiting --> Recruiting
    Enrollment open
    |
    5-fluorouracil • oxaliplatin • irinotecan • leucovorin calcium
    1d
    A Study to Assess Intravenous (IV) Telisotuzumab Adizutecan in Combination With Fluorouracil, Folinic Acid, and Oxaliplatin (FOLFOX) Compared to Standard of Care in Adult Participants With First-Line Metastatic Pancreatic Ductal Adenocarcinoma (clinicaltrials.gov)
    P2/3, N=900, Recruiting, AbbVie | Not yet recruiting --> Recruiting
    Enrollment open
    |
    5-fluorouracil • oxaliplatin • irinotecan • leucovorin calcium • telisotuzumab adizutecan (ABBV-400)
    2d
    FOXHIPECT4: Efficacy of the Use of Neoadjuvant With/Without Hyperthermic Intraperitoneal Chemotherapy in the Treatment of Locally Advanced Colon Cancer (clinicaltrials.gov)
    P3, N=1083, Recruiting, Maimónides Biomedical Research Institute of Córdoba | Not yet recruiting --> Recruiting
    Enrollment open
    |
    5-fluorouracil • oxaliplatin • leucovorin calcium • mitomycin
    2d
    NFYA Activates REG1A Expression to Promote Malignant Progression and Chemosensitivity in Rectal Cancer. (PubMed, Ann Clin Lab Sci)
    NFYA promoted REG1A expression, and the NFYA-REG1A axis enhanced RC resistance to RT and CT and malignant progression.
    Journal
    |
    REG1A (Lithostathine-1-alpha)
    |
    5-fluorouracil
    2d
    A Study of NALIRIFOX in Combination With Radiation Therapy in People With Pancreatic Ductal Adenocarcinoma (PDAC) (clinicaltrials.gov)
    P2, N=60, Recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: May 2026 --> May 2027 | Trial primary completion date: May 2026 --> May 2027
    Trial completion date • Trial primary completion date
    |
    5-fluorouracil • capecitabine • oxaliplatin • leucovorin calcium • Onivyde (nanoliposomal irinotecan)
    2d
    Efficacy and safety of drug-eluting bead transarterial chemoembolization combined with hepatic arterial infusion chemotherapy in unresectable gastric cancer with liver metastasis. (PubMed, Ther Adv Med Oncol)
    Patients underwent 135 sessions using either HepaSphere beads plus HAIC-FOLFOX (HEPA-HAIC, n = 33) or DC bead plus HAIC-FOLFOX (DCB-HAIC, n = 29)...Nausea, vomiting, and severe pain were significantly less frequent with HEPA-HAIC (5.6% vs 31.7%, p = 0.001; 4.2% vs 31.7%, p < 0.001; 8.3% vs 22.2%, p = 0.01). DEB-TACE plus HAIC was feasible and demonstrated intrahepatic disease control with acceptable tolerability in unresectable GCLM; HEPA-HAIC showed a favorable safety profile.
    Journal
    |
    CEACAM5 (CEA Cell Adhesion Molecule 5)
    |
    5-fluorouracil • leucovorin calcium • DC Bead (E7040)
    2d
    Targeting ATF4 overcomes dual resistance to chemo-immunotherapy in gastric cancer by disrupting the DNA damage response. (PubMed, J Immunother Cancer)
    These findings establish the ATF4-HSPA9 axis as a dual-function therapeutic target and predictive biomarker in GC chemo-immunotherapy. This axis bridges DNA damage repair-mediated chemoresistance and T cell exhaustion, providing a strategy to overcome resistance to 5-FU and PD-1 blockade.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    CD8 (cluster of differentiation 8) • ATF4 (Activating Transcription Factor 4) • HSPA9 (Heat Shock Protein Family A (Hsp70) Member ) • TCF4 (Transcription Factor 4)
    |
    5-fluorouracil
    3d
    UC-GIG-2515: Liver-directed chemotherapy after surgery of liver metastases of colorectal cancer in patients withnhigh risk of recurrence of their disease. (2025-523913-27-00)
    P2/3, N=272, Not yet recruiting, Unicancer
    New P2/3 trial
    |
    5-fluorouracil • oxaliplatin • irinotecan • leucovorin calcium • levoleucovorin calcium
    5d
    A Study of 2nd-line FOLFIRI ± Bevacizumab vs. Irinotecan ± Bevacizumab in mCRC (clinicaltrials.gov)
    P3, N=280, Recruiting, Sun Yat-sen University | Unknown status --> Recruiting | Trial completion date: Dec 2018 --> Dec 2026 | Trial primary completion date: Dec 2017 --> Dec 2026
    Enrollment open • Trial completion date • Trial primary completion date
    |
    Avastin (bevacizumab) • 5-fluorouracil • irinotecan • leucovorin calcium
    5d
    Neoadjuvant Intra-tumoral RP2 and FLOT in Gastroesophageal Adenocarcinoma (clinicaltrials.gov)
    P2, N=34, Not yet recruiting, Abramson Cancer Center at Penn Medicine | Initiation date: Apr 2026 --> Sep 2026
    Trial initiation date
    |
    docetaxel • 5-fluorouracil • oxaliplatin • leucovorin calcium • Neulasta (pegfilgrastim) • Neupogen (filgrastim) • sturlimogene erparepvec (RP2)
    5d
    ARC-25: Study of AB598 Monotherapy and Combination Therapy in Participants With Advanced Cancers (clinicaltrials.gov)
    P1, N=40, Active, not recruiting, Arcus Biosciences, Inc. | Trial completion date: Mar 2026 --> Sep 2027 | Trial primary completion date: Mar 2026 --> Sep 2027
    Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 negative
    |
    5-fluorouracil • oxaliplatin • Yutuo (zimberelimab) • leucovorin calcium • AB598